India is witnessing a sharp spike in cardiovascular drug sales, driven by rising heart ailments—especially among the younger population. According to PharmaTrac data, the cardiac drug market has grown nearly 50% over the past five years, reaching ₹30,483 crore as of April 2025.

Key highlights

Significant sales surge

• Cardiac drug sales rose nearly 50% in five years, led by lipid-lowering agents and heart failure therapies.

• Sales of drugs like sacubitril and eplerenone increased 83% in five years and 19% in the last 12 months, touching ₹1,304 crore.

Younger demographics at risk

• Cardiologists report an alarming shift in coronary artery disease to patients aged 25–40.

• One in five heart attack cases in India now involves individuals under 40.

Lifestyle and environmental factors

• Experts cite fast food, lack of physical activity, sleep deprivation, and stress as major contributors.

• Childhood obesity and early exposure to unhealthy habits are further escalating cardiovascular risks.

Expert opinions and national impact

• Dr. Ganesh Kumar AV from LH Hiranandani Hospital highlighted the “unheard-of” rise in young heart patients.

• Amitabh Dube, Novartis India head, emphasized that 25% of all deaths in India are due to cardiovascular disease, with LDL cholesterol emerging as a key driver.

• Dr. Nihar Mehta from Jaslok Hospital noted newer risk factors like air pollution and irregular sleep among youth.

As cardiovascular risk factors extend to younger age groups, the demand for cardiac therapies is surging. Healthcare leaders are calling for urgent lifestyle interventions, better awareness, and early screening to prevent heart disease from becoming an epidemic among India’s youth.